AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Accolade Inc. (ACCD)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

6.88

0.02 (0.29%)

At close: Jan 17, 2025, 3:59 PM

6.88

0.00%

After-hours Jan 17, 2025, 04:11 PM EST

undefined% (undefined)

Bid	6.87
Market Cap	561.95M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.28
PE Ratio (ttm)	-3.02
Forward PE	n/a
Analyst	Hold

Ask	6.89
Volume	2,227,902
Avg. Volume (20D)	1,826,063
Open	6.86
Previous Close	6.86
Day's Range	6.85 - 6.90
52-Week Range	3.08 - 13.93
Beta	undefined

About ACCD

Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also prov...

[Show more]

Industry Medical - Healthcare Information Services

Sector Healthcare

IPO Date Jul 1, 2020

Employees 2,400

Stock Exchange NASDAQ

Ticker Symbol ACCD

Website https://www.accolade.com

Analyst Forecast

According to 11 analyst ratings, the average rating for ACCD stock is "Hold." The 12-month stock price forecast is $6, which is a decrease of -12.79% from the latest price.

Buy 27.27%

Hold 72.73%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Accolade Inc. is scheduled to release its earnings on Apr 24, 2025, during market hours.
Analysts project revenue of $142.39M, reflecting a 14.07% YoY growth and earnings per share of 0.21, making a -310.00% decrease YoY.

Why Price Moved

1 week ago · Source

+104.78%

Accolate shares are trading higher after the compa... Unlock content with Pro Subscription

3 months ago · Source

+5.87%

Accolade shares are trading higher. Needham reiterated a Buy rating on the stock and maintained a price target of $8.

News

1 week ago · zacks.com

Accolade (ACCD) Reports Q3 Loss, Lags Revenue Estimates

Accolade (ACCD) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.28 per share a year ago.

1 week ago · businesswire.com

ACCOLADE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Accolade, Inc. - ACCD

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Accolade, Inc. (...

1 week ago · benzinga.com

Why Is Accolade Stock Trading Over 100% On Tuesday?

Transcarent agreed to buy Accolade Inc ACCD Wednesday for $621 million.

1 week ago · businesswire.com

Shareholder Alert: Ademi LLP Investigates Whether Accolade, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Accolade (NASDAQ: ACCD) for possible breaches of fiduciary duty and other violations of law in its transaction with the Transcarent. Click here t...

1 week ago · businesswire.com

Transcarent To Acquire Accolade

SAN FRANCISCO & SEATTLE--(BUSINESS WIRE)-- #HealthWayFinding--Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and prim...

1 month ago · seekingalpha.com

Accolade: A GARP Stock Trading Well Under 1X Revenues

Accolade, Inc. is a promising buy due to tax loss season, with potential for a January recovery and long-term growth prospects. The stock's significant drop is attributed to IPO fallout and an overrea...

1 month ago · zacks.com

Accolade (ACCD) Upgraded to Buy: Here's Why

Accolade (ACCD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago · businesswire.com

Porter Airlines Receives Another Accolade with APEX Four Star Major Airline Rating

TORONTO--(BUSINESS WIRE)--Porter Airlines has been rated a 2025 Four Star Major Airline by passengers, certified by the Airline Passenger Experience Association (APEX). The APEX Five Star and Four Sta...

2 months ago · zacks.com

Accolade (ACCD) Loses -15.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Accolade (ACCD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates ...